Warner-lambert Company

Juan C Jaen

Lawrence D Wise

Bradley W Caprathe

Sarah J Smith

David Juergen Wustrow

Haile Tecle

Shelly Ann Glase

Donna M Reynolds

David G Nickell

Anthony J Thomas

Corinne E Augelli-Szafran

Stephen Douglas Barrett

Stephen J Johnson

Sheryl Jeanne Hays

Jonathan L Wright

Dennis M Downing

Horace A DeWald

Stephen C Bergmeier

William J Smith, Iii

John Lodge Gilmore

David J Lauffer

Walter H Moos

Michael R Pavia

Edgardo Laborde

Harry LeVine, Iii

Mark M Gleason

Howard Yoshihisa Ando

Roy Douville Schwarz

Steven Edward Rose

Adam A Galan

Kathryn B Sanders

Ruth Bucsh

Jan Ruth Penvose-Yi

Xi Chen

Jeffrey P Mcmahon

Penglie Zhang

Yibin Zeng

Pingchen Fan

Jay Powers

Lianfa Li

Method of imaging amyloid deposits

This invention concerns certain 2-substituted-3,1-benzoxazin-4-ones and benzthiazinones as complement Clr protease inhibitors and antiinflammatory agents, pharmaceutical compositions containing them, methods of using them, and processes for their preparation.

2-substituted-4H-3, 1-benzoxazin-4-ones and benzthiazin-4-ones as

Substituted tetrahydropyridines and hydroxypiperidines and derivatives thereof are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as central nervous system agents and are particularly useful as dopaminergic, antipsychotic, and antihypertensive agents as well as for treating hyperprolactinaemia-related conditions and central nervous system disorders.

Substituted tetrahydropyridines and hydroxypiperidines as central

The [1:1] maleate salt of [R-(Z)]-1-Azabicyclo [2.2.1]heptan-3-one, O-[3-(3-methoxyphenyl)-2-propynyl]-oxime, a known muscarinic agonist has unique properties relative to other salts of the compound, rendering it a desirable pharmaceutical.

(R)-(Z)-1-azabicyclo [2.2.1]

The instant invention is a selective formation of the Z-oxime and O-alkylation of 1-azabicyclo 2.2.1!heptan-3-one and 1-azabicyclo 2.2.2!heptan-3-one oximes to produce compounds with muscarinic activity. The process is capable of scale-up for industrial purposes as it provides better yields and ease of preparation. Intermediates are also described.

Preparation of stereochemically pure oximes with muscarinic activity

Substituted tetrahydrophyridines and hydroxypiperidines as central

Substituted tetrahydropyridines and piperidinecarboxylic acids and derivatives thereof are described, as well as methods for the preparation and pharmaceutical composition of same, which muscarinic antagonists are useful as agents for inhibiting gastric acid release, for treating bradycardia, bronchoconstriction, urinary incontinence, atonic conditions of the gut and bladder, Parkinson's disease, dystonias, and Alzheimer's disease.

Substituted tetrahydropyridine and piperidine carboxylic acids as

1,3-Substituted cycloalkenes and cycloalkanes are described, as well as methods for the preparation and pharmaceutical composition of same, which are useful as central nervous system agents and are particularly useful as dopaminergic, antipsychotic, and antihypertensive agents as well as for treating hyperprolactinaemia-related conditions and central nervous system disorders.

1,3-substituted cycloalkenes and cycloalkanes as central nervous system

Pharmaceutically useful nitrogen containing cyclic oxime and amine substituted compounds which are azabicyclo[2.2.1]oximes, azabicyclo[2.2.2]oximes, azabicyclo[2.2.1]amines, azabicyclo[2.2.2]amines, azabicyclo[3.2.1]oximes, and amine containing heterocyclic oximes wherein the heterocyclic ring contains from 3 to 7 carbon atoms are disclosed.

Azabicyclo and azacyclo oxime and amine cholinergic agents and methods

Pyrazolo[5,1-b]quinazoline compounds, salts thereof, methods of production, intermediates in their production, pharmaceutical compositions containing said compounds, and methods for treating neurodegenerative disorders, tumors of neuronal origin, inflammation, allergy, and pain, and methods for screening compounds that interact with the neurotrophic receptors using said compositions are disclosed.

Pyrazoloquinazolone derivatives as neurotrophic agents

Fused pyridazinoquinazoline compounds, salts thereof, methods of production, intermediates in their production, pharmaceutical compositions containing said compounds and methods for treating neurodegenerative disorders using said compositions are disclosed.

Fused pyridazinoquinazolone derivatives as neurotrophic agents

Substituted piperazines and derivatives of Formula I ##STR1## are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as central nervous system agents and are particularly useful as dopaminergic, antipsychotic, and antihypertensive agents as well as for treating hyperprolactinaemia-related conditions and central nervous system disorders.

Substituted piperazines as central nervous system agents

Substituted 1,2,3,6-tetrahydropyridines are described, as well as methods for the preparation and pharmaceutical composition of same, which are useful as central nervous system agents and are particularly useful as dopaminergic, antipsychotic, and antihypertensive agents as well as for treating hyperprolactinaemia-related conditions and central nervous system disorders.

Substituted 1,2,3,6-tetrahydropyridines as central nervous system agents

Growing community of inventors

Plymouth, MI, United States of America

Juan C Jaen